35-kDa Hyaluronan Fragment (HA35) Chewable Tablets for Gingival Inflammation, Oral Pain and Pharyngeal Discomfort (HA35-CHEW)
Prospective Single-Arm Open-Label Clinical Study of 35-kDa Hyaluronan Fragment (HA35) Chewable Tablets for Gingival Pain, Periodontal Inflammation, Gingival Recession and Pharyngeal Itch-Pain
To explore efficacy and safety of 35-kDa hyaluronan fragment (HA35) chewable tablets for relief of tooth-gingival pain, periodontal gingival inflammation, mild gingival recession, and pharyngeal itching-pain. Participants chew six tablets per dose, three times daily for 28 consecutive days. Assess subjective oral-pharyngeal symptoms, gingival inflammation, estimated gingival regrowth and safety events.
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Detaljert beskrivelse
This is prospective, single-arm, open-label pilot clinical study. Eligible adult participants with periodontal condition, mild gingival recession and oral-gingival pain or pharyngeal discomfort receive HA35 chewable tablets. Each tablet weighs 600 mg containing 300 mg 35-kDa hyaluronan fragment. Subjects chew six tablets each administration (3 tablets on each molar side), three times daily for total 18 tablets/day (5.4 g HA35/day), for 28 consecutive days. Tablets dissolve by saliva in oral cavity after chewing. Evaluations are performed at baseline; 3 minutes post-first dose; 30 minutes post-first dose; Day 1, Day 7, Day 21, Day 28. Investigator assess gingival redness/swelling, exposed root length for estimated gingival regrowth. Subject self-report pain, itch-pain of throat. Exploratory facial-tissue related assessments are performed at Day 28. Adverse events are monitored throughout whole 28-day study period. Target enrollment: 30 adult participants.
Studietype
Studietype
Registrering (Antatt)
Registrering
Fase
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
Studiekontakt
- Navn: Mizhou Hui
- Telefonnummer: 13484005199
- E-post: mizhou.hui@alumni.utoronto.ca
Studiesteder
-
-
Shandong
-
Qingdao, Shandong, Kina
- Nakhia Impex LLC
-
Ta kontakt med:
- Xiaoxiao Jia
- Telefonnummer: 15621486915
- E-post: 15621486915@163.com
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Age 18-75 years old, male or female adult.
- Clinical findings of periodontal disease with mild gingival recession; with at least one of following: chronic gingival/tooth-root pain; pain after dental procedure (restoration, scaling, extraction, transplantation etc.); subjective pharyngeal itching or pharyngeal pain.
- Able to independently complete NRS scale self-assessment.
- Able to follow full 28-days three-times-daily chewable-tablet protocol.
- Voluntarily sign written informed-consent document.
Exclusion Criteria:
- Severe periodontal disease requiring immediate surgical intervention; active oral ulcer, oral malignant lesion.
- Pregnant or lactating women.
- Known hypersensitivity / allergy to hyaluronan / sodium hyaluronate or tablet excipients.
- Severe gastrointestinal diseases.
- Simultaneous participation in other oral-pharyngeal-related clinical trials.
- Psychiatric disorders that compromise study compliance.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: HA35 Chewable Tablets
|
Intervention description: Each tablet 600 mg containing 300 mg HA35. Chew six tablets per dose (3 each side molars), three times daily, total 18 tablets/day (5.4 g HA35/day), 28 consecutive days. Tablets dissolve in saliva after chewing. |
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Primary Outcome Measures
Tidsramme: Baseline, 3 minutes after first administration, Day-1, Day-7, Day-28
|
Participant-reported 0-10 numerical rating scale for tooth and gingival pain; 0=no pain,10=worst imaginable pain |
Baseline, 3 minutes after first administration, Day-1, Day-7, Day-28
|
|
Pharyngeal Itching-Pain NRS Score
Tidsramme: Baseline,30 minutes after first administration, Day-1, Day-7, Day-28
|
Participant-reported 0-10 NRS for throat itching and pain;0=no symptom, 10=worst imaginable itch-pain |
Baseline,30 minutes after first administration, Day-1, Day-7, Day-28
|
|
Gingival Inflammatory Redness-Swelling NRS Score
Tidsramme: Baseline, Day-1, Day-7, Day-21, Day-28
|
Investigator-rated composite 0-10 score of gingival redness and swelling;0=no inflammation;10=severe gingival redness and swelling |
Baseline, Day-1, Day-7, Day-21, Day-28
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Estimated Gingival Regrowth Length (mm)
Tidsramme: Baseline, Day-21, Day-28
|
Investigator measurement of exposed tooth-root length using 1-mm precision ruler; calculate estimated gingival regrowth from baseline |
Baseline, Day-21, Day-28
|
|
Exploratory Facial-tissue Reduction Score
Tidsramme: Baseline, Day-28
|
Investigator visual-tactile 0-10 rating scale (exploratory only): reduction of facial roundness, forehead-skin thickness, eyelid thickness, double-chin prominence;0=no reduction;10=maximum reduction. Exploratory endpoint only |
Baseline, Day-28
|
|
Participant Overall Satisfaction Score
Tidsramme: Day-28 end-of-treatment
|
Participant self-reported overall satisfaction 0-10 scale for oral-pharyngeal improvement. 0=most dissatisfied, 10=most satisfied |
Day-28 end-of-treatment
|
|
Adverse Event Incidence
Tidsramme: Entire 28-day study period
|
Incidence of product-related adverse events including oral mucosal irritation, hypersensitivity, gastrointestinal discomfort, throat irritation |
Entire 28-day study period
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- HA35202612
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .